Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochen Tuettenberg

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Tumori|April 26, 2007
Efficacy of different regimens of adjuvant radiochemotherapy for treatment of glioblastomaAntonella Scheda, Janvier Kaba Finjap, Jochen Tuettenberg, et al.
Journal of Cancer Research and Clinical Oncology|February 24, 2010
Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institutionMarcel Seiz, Ulrich Krafft, Christian F Freyschlag, et al.
International Immunopharmacology|March 27, 2012
Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patientsJochen Tuettenberg, Marcel Seiz, Klaus-Michael Debatin, et al.
Oncology|September 13, 2019
Open-Label Phase II Evaluation of Imatinib in Primary Inoperable or Incompletely Resected and Recurrent GlioblastomaLisa Sautter, Ralf Hofheinz, Jochen Tuettenberg, et al.
Anticancer Research|August 8, 2009
First experiences with low-dose anti-angiogenic treatment in gliomatosis cerebri with signs of angiogenic activityMarcel Seiz, Patricia Kohlhof, Marc Alexander Brockmann, et al.
Neuro-Oncology|May 17, 2007
Preoperative thrombocytosis predicts poor survival in patients with glioblastomaMarc A Brockmann, Alf Giese, Kathrin Mueller, et al.
International Journal of Cancer|December 18, 2008
Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cellsNicole Schwinn, Daria Vokhminova, Antje Sucker, et al.
Cancer|April 29, 2014
Mutant IDH1 inhibits PI3K/Akt signaling in human gliomaPeter Birner, Stefan Pusch, Christo Christov, et al.
Cancers|December 23, 2023
Nuclear Glycoprotein A Repetitions Predominant (GARP) Is a Common Trait of Glioblastoma Stem-like Cells and Correlates with Poor Survival in Glioblastoma PatientsNiklas Zimmer, Emily R Trzeciak, Andreas Müller, et al.
Anticancer Research|August 9, 2015
Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard TreatmentJohannes Kerschbaumer, Franziska Anna Schmidt, Astrid Ellen Grams, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Tumori|April 26, 2007
Efficacy of different regimens of adjuvant radiochemotherapy for treatment of glioblastomaAntonella Scheda, Janvier Kaba Finjap, Jochen Tuettenberg, et al.
Journal of Cancer Research and Clinical Oncology|February 24, 2010
Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institutionMarcel Seiz, Ulrich Krafft, Christian F Freyschlag, et al.
International Immunopharmacology|March 27, 2012
Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patientsJochen Tuettenberg, Marcel Seiz, Klaus-Michael Debatin, et al.
Oncology|September 13, 2019
Open-Label Phase II Evaluation of Imatinib in Primary Inoperable or Incompletely Resected and Recurrent GlioblastomaLisa Sautter, Ralf Hofheinz, Jochen Tuettenberg, et al.
Anticancer Research|August 8, 2009
First experiences with low-dose anti-angiogenic treatment in gliomatosis cerebri with signs of angiogenic activityMarcel Seiz, Patricia Kohlhof, Marc Alexander Brockmann, et al.
Neuro-Oncology|May 17, 2007
Preoperative thrombocytosis predicts poor survival in patients with glioblastomaMarc A Brockmann, Alf Giese, Kathrin Mueller, et al.
International Journal of Cancer|December 18, 2008
Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cellsNicole Schwinn, Daria Vokhminova, Antje Sucker, et al.
Cancer|April 29, 2014
Mutant IDH1 inhibits PI3K/Akt signaling in human gliomaPeter Birner, Stefan Pusch, Christo Christov, et al.
Cancers|December 23, 2023
Nuclear Glycoprotein A Repetitions Predominant (GARP) Is a Common Trait of Glioblastoma Stem-like Cells and Correlates with Poor Survival in Glioblastoma PatientsNiklas Zimmer, Emily R Trzeciak, Andreas Müller, et al.
Anticancer Research|August 9, 2015
Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard TreatmentJohannes Kerschbaumer, Franziska Anna Schmidt, Astrid Ellen Grams, et al.
Pageof 4